Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ViaLase Closes $40 million Series C Financing to Advance First Femtosecond Laser for the Treatment of Glaucoma | ||||||||
By: PR Newswire Association LLC. - 01 Apr 2024 | Back to overview list |
|||||||
Series C financing supports the continued advancement of ViaLase's clinical, regulatory and commercial milestones ALISA VIEJO, Calif., April 1, 2024 /PRNewswire/ -- ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it has closed a Series C financing raising gross proceeds of approximately $40 million. The financing was led by a new investor along with strong support from current investors, including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision, an ophthalmology investment platform supported by KKR. ViaLase's approach to glaucoma management has the potential to elevate the standard of care for glaucoma patients. Proceeds from this round of financing will ensure the continued advancement of clinical, regulatory, and commercial milestones of the Company's ViaLase® Laser*. If approved, the ViaLase Laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma (POAG). "ViaLase's innovative approach to glaucoma management has the potential to elevate the standard of care for glaucoma patients around the world," said Jim Adox, Executive Managing Director, Venture Investors. "We have strongly believed in ViaLase's proven leadership, brilliant team, and pioneering technology since we wrote the first seed check to back the team." "The strong support from our investors validates the potential of the ViaLase Laser to enhance the current treatment paradigm for the millions of patients living with glaucoma," said Tibor Juhasz, PhD, Founder and Chief Executive Officer, ViaLase, Inc. "We are preparing to embark on a new phase in our company's evolution—commercialization —and are incredibly fortunate to have the support, resources, financial backing and counsel of such a high-caliber group of investors." The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver a noninvasive glaucoma treatment called femtosecond laser image-guided high-precision trabeculotomy, or FLigHT. The novel FLigHT procedure will provide physicians with unparalleled precision and visibility when creating channels in the trabecular meshwork (TM) to lower intraocular pressure (IOP) through a noninvasive, nonsurgical approach. About Glaucoma About ViaLase, Inc. About Venture Investors Health Fund About Arboretum Ventures About Falcon Vision *The ViaLase Laser is an investigational device and is not approved for commercial use. References:
Any product, brand names, and/or logos are trademarks of ViaLase, Inc. MEDIA CONTACT: View original content to download multimedia:https://www.prnewswire.com/news-releases/vialase-closes-40-million-series-c-financing-to-advance-first-femtosecond-laser-for-the-treatment-of-glaucoma-302104074.html SOURCE ViaLase, Inc. |
||||||||
|
||||||||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |